MST1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1709769	0.64	3/20
SCHEMBL14547916	0.56	3/20
SCHEMBL14547772	0.55	3/20
SCHEMBL14547938	0.50	3/20
SCHEMBL3711845	1.00	2/20
SCHEMBL3703928	0.67	2/20
SCHEMBL14547857	0.64	2/20
SCHEMBL14547856	0.58	2/20
SCHEMBL1709844	0.57	2/20
SCHEMBL1709807	0.57	2/20
SCHEMBL3705241	0.57	2/20
SCHEMBL22068318	0.57	2/20
SCHEMBL1709880	0.56	2/20
SCHEMBL3709370	0.56	2/20
SCHEMBL14547730	0.56	2/20
SCHEMBL1709874	0.55	2/20
SCHEMBL3713533	0.55	2/20
SCHEMBL14547766	0.55	2/20
SCHEMBL1709875	0.55	2/20
SCHEMBL14547759	0.55	2/20

Clinical trials — most relevant to MST1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients	PHASE3	COMPLETED
Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy	PHASE2	COMPLETED
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients	PHASE2	ENROLLING_BY_INVITATION
SCARFREE-001: Verteporfin for Scar Prevention	PHASE2	NOT_YET_RECRUITING
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
Temsirolimus as Second-line Therapy in HCC	PHASE2	UNKNOWN
Randomized Phase II Trial of Chemoembolization and Sorafenib	PHASE2	WITHDRAWN
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas	PHASE1/PHASE2	COMPLETED
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer	PHASE2	COMPLETED
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Pazopanib and ARQ 197 for Advanced Solid Tumors	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor	PHASE1	COMPLETED
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	PHASE1	COMPLETED
Beta-Hydroxy-Beta-Methylbutyrate Supplementation and Physical Activity in Liver Cirrhosis: a Controlled Trial	nan	UNKNOWN
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation	nan	COMPLETED
ACTLIFE: is Active Life-style Enough?	nan	UNKNOWN
Clinical Study to Evaluate Safety and Efficacy of Amino Acid in Healthy Individuals	nan	COMPLETED
The Effect of Blood Flow Restriction (Bfr) Exercise on Acute Systemic Myokine Levels in Healthy Trained Men	nan	UNKNOWN
Epithelioid Haemangioendothelioma Observational Study	nan	RECRUITING
Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)	nan	RECRUITING
The Activation of Hippo Pathway in Nasal Polyps	nan	UNKNOWN
Elucidating Growth Hormone Dynamics at Stages of Progressive Nonalcoholic Fatty Liver Disease	nan	UNKNOWN
Tumor Kinase Inhibitor Concentrations Measured by PET	nan	COMPLETED
Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular Carcinoma	nan	RECRUITING
A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET	nan	RECRUITING
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC)	nan	COMPLETED
VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MST1 binder may also engage these)

Protein	Name	Similarity
P26928	—	0.998	P26928 →
Q24K22	—	0.996	Q24K22 →
D3ZTE0	—	0.990	D3ZTE0 →
Q80YC5	—	0.988	Q80YC5 →
Q5R8J0	—	0.988	Q5R8J0 →
P11214	—	0.988	P11214 →
P18292	—	0.987	P18292 →
PLG	Plasminogen	0.986	landscape →
Q5G265	—	0.986	Q5G265 →
HGF	Hepatocyte growth factor	0.986	landscape →
P19637	—	0.986	P19637 →
Q08048	—	0.986	Q08048 →
P17945	—	0.986	P17945 →
Q5R537	—	0.985	Q5R537 →
Q5R8X6	—	0.985	Q5R8X6 →
F7	Coagulation factor VII	0.985	landscape →
O97507	—	0.985	O97507 →
Q9R098	—	0.985	Q9R098 →
ST14	Suppressor of tumorigenicity 14 protein	0.985	landscape →
P20918	—	0.985	P20918 →
P06868	—	0.985	P06868 →
Q8SQ23	—	0.984	Q8SQ23 →
P49150	—	0.984	P49150 →
Q29485	—	0.984	Q29485 →
O08762	—	0.984	O08762 →
Q5G270	—	0.984	Q5G270 →
Q5G266	—	0.983	Q5G266 →
P04185	—	0.983	P04185 →
Q2F9P2	—	0.983	Q2F9P2 →
Q6IE64	—	0.983	Q6IE64 →